L-fucose Treats Infectious Diseases and Cancers - US20260108547A1
Summary
The USPTO has published patent application US20260108547A1, filed on October 4, 2023, disclosing methods for treating infectious diseases and cancers by administering L-fucose to a subject. The application names Eric LE-LAU as inventor and claims therapeutic uses of the monosaccharide L-fucose in medical treatments. This patent publication establishes prior art and may affect freedom-to-operate analyses for competing therapeutics developers.
“Disclosed are methods for treating infectious diseases and cancers comprising administering to a subject a L-fucose.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO has published patent application US20260108547A1, filed on October 4, 2023, disclosing methods for treating infectious diseases and cancers by administering L-fucose to a subject. The application names Eric LE-LAU as inventor and claims therapeutic uses of the monosaccharide L-fucose in medical treatments. This patent publication establishes prior art and may affect freedom-to-operate analyses for competing therapeutics developers.
Pharmaceutical companies developing carbohydrate-based therapeutics and medical researchers in immunology and infectious disease fields should review this application's claims for prior art purposes and potential freedom-to-operate implications.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
LEVERAGING L-FUCOSE-MEDIATED SIGNALING TO INDUCE MONOCYTE-DERIVED DENDRITIC CELL POLARIZATION
Application US20260108547A1 Kind: A1 Apr 23, 2026
Inventors
Eric LE-LAU
Abstract
Disclosed are methods for treating infectious diseases and cancers comprising administering to a subject a L-fucose.
CPC Classifications
A61K 31/7004 A61K 39/3955 A61K 40/42 A61P 35/00 A61K 2039/505
Filing Date
2023-10-04
Application No.
19118148
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.